NovoCodex Biopharmaceuticals Co., Ltd. announced that it has received CNY 400 million in funding from Eli Lilly Investment Consulting Co., Ltd., Jingwei Venture Capital Investment Management Consulting Co., Ltd., Hangzhou Sanhua Hongdao Investment Management Partnership (L.P.), SDIC Capital Co.,Ltd
March 18, 2021
Share
NovoCodex Biopharmaceuticals Co., Ltd. announced that it has received CNY 400 million in its series A round of funding co-led by Eli Lilly Investment Consulting (Shanghai) Co., Ltd., and Jingwei Venture Capital (Beijing) Investment Management Consulting Co., Ltd. on March 19, 2021. The transaction also involved participation from Hangzhou Sanhua Hongdao Investment Management Partnership (L.P.) and SDIC Capital Co.,Ltd.
SDIC Capital Co., Ltd, formerly SDIC Essence (Holdings) Co., Ltd, is a China-based company principally engaged in the securities business. The Company operates through five segments. The Brokerage segment manily includes brokerage business of securities and futures and the agent sales of financial products. Entrusted Asset Management segment mainly includes the pooled asset management, directional asset management and specific asset management. Proprietary Business segment mainly invests the Companyâs funds in equity securities, fixed income securities and derivatives and is involved in the market making business in the new over-the-counter (OTC) market. Investment Banking segment includes stock financing, bond financing, mergers and acquisitions and financial advisory services. Margin Trading segment includes margin trading, stock pledged repo and agreed-to-repurchase securities.
NovoCodex Biopharmaceuticals Co., Ltd. announced that it has received CNY 400 million in funding from Eli Lilly Investment Consulting Co., Ltd., Jingwei Venture Capital Investment Management Consulting Co., Ltd., Hangzhou Sanhua Hongdao Investment Management Partnership (L.P.), SDIC Capital Co.,Ltd
SDIC CAPITAL CO.,LTD 
